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ABSTRACT
OBJECTIVE: We aimed to investigate whether mitochondrial ATP-sensitive potassium (mitoKATP) channels play 
any role on cardiovascular effects of thiopental (TP) or ketamine (K) anesthesia in rats.
BACKGROUND: mitoKATP channels are the end-effectors of cardioprotection induced by some anesthetics. TP and K 
are the most frequently used anesthetics with their own cardiovascular effects in experimental studies. To the best of 
our knowledge, there is no study investigating the cardiovascular effects of TP and K associated with mitoKATP channels.
MATERIALS AND METHODS: The experimental groups: TP control, K/Xylazine (X) control, TP+5-hydroxydecano-
ate (5-HD; mitoKATP channel blocker) and K/X+5-HD. Mean arterial blood pressure (MABP), heart rate (HR) and 
standard limb lead II ECG were recorded and arrhythmia parameters were evaluated. 
RESULTS: Blockage of mitoKATP channels by 5-HD increased MABP and decreased HR in the TP+5-HD and K/
X+5-HD groups, respectively. 5-HD caused an increase in ventricular ectopic beat (VEB) incidence. Moreover, 
VEB incidence was signifi cantly different in TP+5-HD (100 %) than K/X+5-HDgroup (66.6 %) and ventricular 
tachycardia was only seen in TP+5-HD (incidence was 88.3 %). 
CONCLUSION: mitoKATP channels play different roles in infl uencing cardiovascular effects of K/X and TP anesthesia 
in rats. The differences in hemodynamic parameters and arrhythmia scores of these anesthetics should be considered 
when they are used in an experimental study associated with mitoKATP channels (Fig. 3, Ref. 35). Text in PDF www.elis.sk.
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Introduction
Anesthesia is an essential part of the surgical process that 
removes sensory functions temporarily, depresses the nervous 
system and so causes blackout of consciousness. In experimental 
animals, anesthetics are being widely used to prevent sensation of 
fear and pain of animals associated with surgical procedure, protect 
the researcher and provide safely and an easy surgical approach. 
The purpose of the experiment, type and duration of the surgical 
procedure, species of the animal, experience of the researcher are 
the main factors when choosing the anesthetic. However, anes-
thetics can effect a great number of organ systems, so choosing 
the anesthetic has a great impact on the experimental protocol (1).
Thiopental (TP) is the most frequently used barbiturate as a 
general anesthetic in experimental animals. Although TP could 
reduce blood pressure and cardiac contractility, it does not cause 
severe arrhythmia. So TP is preferred especially in designing ex-
periments associated with cardiovascular system. Ketamine (K) 
is frequently used as a parenteral dissociative anesthetic without 
its visceral analgesic effect. Ketamine anesthesia increases heart 
rate, systemic blood pressure, pulmonary
arterial pressure and cardiac output (2). Xylazine (X), an α2-
adrenoceptor agonist, has sedative and analgesic effects but it is 
not accepted as a general anesthetic. Addition of X to K anesthesia 
is frequently used to eliminate the undesirable effects (delirium, 
increase of secretion) of K.
ATP-sensitive potassium (KATP) channels were isolated from 
different tissues, e.g. ventricle myocytes, brain, smooth muscle, 
skeletal muscle and pancreas. It has been reported that opening 
of the myocardial KATP channels is an endogenous protective 
mechanism against ischemic injury (3) and also mediates protec-
tive effects of ischemic- or anesthetic-induced preconditioning 
(4, 5). In addition to sarcolemmal KATP channels, activation of 
mitochondrial KATP (mitoKATP) channels which are located on mi-
tochondrial inner membrane, is involved as a trigger in ischemic 
preconditioning/cardio-protection by different subcellular mecha-
nisms (6). The opening of mitoKATP channels induces an increase 
in K+ current, that is enough to change the mitochondrial volume 
without an important depolarization of the membrane (7, 8). It is 
suggested that changing the volume of mitochondria has important 
effects on cell energy coupling. This mild depolarization of the 
mitochondrial membrane potential by opening mitoKATP channels 
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also limits mitochondrial Ca2+ loading by decreasing the driving 
force for Ca2+ infl ux (9).
5-hydroxydecanoate (5-HD) blocks selectively mitoKATP chan-
nels (10–12) and in this way it may attenuate the ischemic or 
pharmacological preconditioning of the heart. Although there are 
some studies which suggest that 5-HD blocks also the sarcolem-
mal KATP channels, it is also known that 5-HD is much more potent 
on mitoKATP channels (13, 14). 
The mitoKATP channels are the end-effectors of the cardio-
protection of volatile anesthetics (5, 9). TP and K are the most 
frequently used anesthetics with their own cardiovascular effects 
in experimental studies. But there is no study investigating the 
cardiovascular effects of TP and K associated with mitoKATP chan-
nels. So the aim of the present study was to investigate whether 
mitoKATP channels play any role on cardiovascular effects of thio-
pental (TP) or ketamine (K) anesthesia in rats.
Materials and methods
This study was approved by the Baskent University Ethical 
Committee for Experimental Research on Animals (DA 10/11). All 
experiments were performed on male Wistar Albino rats (n = 22, 
250–450 g). The rats were housed in cages at room temperature 
21 ± 1 °C, under 12/12 hours light/dark cycle and were allowed 
“ad libitum” access to standard laboratory diet and tap water. In 
anesthetized animals tracheotomy was performed and they were 
mechanically ventilated with room air with the help of the animal 
ventilator (Rodent Ventilator 7025 UgoBasile, 5 mL/100 g, 34 
pulse/min room air). Body temperature of the experimental ani-
mals was maintained at 37 ± 1 °C. A standard limb lead II elec-
trocardiogram (ECG) and heart rate were continuously monitored 
and recorded throughout the experiment, using electrocardiograph 
(ECG 100B; Biopac. System Inc.) and a computerized data ac-
quisition system. After the right jugular vein cannulation, saline 
(0.8 mL/h) was continually administered during the experiments 
with an infusion pump (JMS SP-100s). The left carotid artery was 
cannulated with a heparinized saline fi lled catheter connected to 
a pressure transducer (MAY GTA200) for arterial blood pressure 
monitoring. After all the surgical procedures had been performed, 
related records were monitored and saved during the 10-minute 
period through MP100 system (Biopac Systems, Inc.). At the end 
of the experimental protocol, the rats were sacrifi ced with a high 
dose anesthetic.
The study animals were divided into groups as follows:
I. Thiopental control group (TP control, n = 5): Rats were anes-
thetized with thiopental sodium (75 mg/kg, i.p.) (15),
II. Ketamine/xylazine control group (K/X control, n  =5): Rats 
were anesthetized with ketamine/xylazine (60/10 mg/kg, i.p.) (16),
III. Thiopental+5-hydroxydecanoate group (TP+5-HD, n = 
6): 5-hydroxydecanoate (5-HD, 50 ng/g, i.p.) was administered 5 
minutes before the thiopental sodium (75 mg/kg, i.p.) anesthesia,
IV. Ketamine/xylazine+5-hydroxydecanoate group (K/X+5-
HD, n = 6): 5-hydroxydecanoate (5-HD, 50 ng/g, i.p.) was ad-
ministered 5 minutes before the ketamine/xylazine (60/10 mg/
kg, i.p.) anesthesia.
Statistical analysis
Statistical evaluation was performed by Graph Pad Software. 
Data are expressed as mean ± S.E.M or the percentage of inci-
dence. For repeated measurements, two-way ANOVA was used 
in hemodynamic parameters. Incidence of arrhythmia was evalu-
ated by Fisher’s exact test, p < 0.05 was considered to indicate 
statistical signifi cance.
Results
The hemodynamic parameters including mean arterial blood 
pressure (MABP) and heart rate (HR) were monitored during the 
10-minute period for the experimental protocol. MABP and HR 
were not signifi cantly different in TP control and K/X control 
groups. However blockage of the mitoKATP channels by 5-HD, 
MABP was increased signifi cantly only in TP+5-HD group when 
compared to its own control group. But there was no signifi cant 
difference in MABP between K/X+5-HD and its control group 
(Fig. 1). Furthermore, blockage of the mitoKATP channels by 5-HD 
caused a decrease in HR only in K/X+5-HD compared with its 
control group (Fig. 2).
At the end of the experimental protocol, the arrhythmia pa-
rameters were evaluated from ECG records of experiment animals 
in accordance with the Lambeth conventions (17). The incidence 
of ventricular ectopic beat (VEB), ventricular tachycardia (VT) 
and ventricular fi brillation (VF) were determined in each group. 
Severe arrhytmogenic effects were evaluated with the mitoKATP 
channel blocker (Fig. 3). Blockage of mitoKATP channels by 5-HD 
signifi cantly increased the VEB incidence when compared with 
their control groups. Moreover, the incidence of VEB in TP+5-
HD (100  was signifi cantly different from K/X+5-HD group (66.6 
%). During the experimental protocol, VT was not observed in TP 
control, K/X control and K/X+5-HD groups. But VT was observed 
in TP+5-HD group with 88.3 %incidence. VF was not observed 
in any experimental group.
Discussion
It is an important to bear in mind that anesthetics which will 
be used in experimental studies, especially related with cardio-
vascular system, may affect hemodynamic parameters and ar-
rhythmia scores differently. One of the reasons of this could be 
that the anesthetic has different effects associated with different 
mechanisms (i.e. mitoKATP channel, oxidative stress). This may 
explain the inconsistent results in many articles in the literature.
Oxidative stress results from imbalance between oxidants and 
antioxidants in favor of the oxidants (18). It causes excessive pro-
duction of reactive oxygen species (ROS). Indeed, redox signaling 
has regulatory role on several physiological processes in the heart 
(i.e. excitation-contraction coupling) (19). However, excess accu-
mulation of ROS induces a chain of reactions in cardiovascular 
pathological processes such as hypertension, ischemia/reperfusion 
injury (20). It has been reported that markers of oxidative stress 
(such as malondialdehyde, superoxide dismutase and catalase) 
are affected by ketamine and thiopental to different degrees (21). 
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Mitochondria is the main target and end effector for a number 
of cellular metabolic processes including cell-signaling cascades, 
redox control, ion homeostasis and cell death. Mitochondria are im-
portant in relation to oxidative stress because it is the main source 
for pathological ROS production (22). It has also been known that 
impaired mitochondrial function is the most important reason of 
reperfusion injury, e.g. apoptosis, necrosis and cell death (23). That 
is why mitochondria is the main target of protective interventions 
against reperfusion injury. Impairment of cardiac mitochondrial 
function after ischemia or ischemia/reperfusion causes a decrease 
in the adenine nucleotide content of myocytes, impairment in the 
adenine nucleotide translocase activity, depression of the respira-
tory chain complex activity, attenuation in membrane potential and 
decrease in NADH dehydrogenase activity (23–28). Considering 
all this energy related changes in reperfusion injury, opening of 
the mitoKATP channels seems to be important to protect the heart. It 
has already been reported that mitoKATP channels in the heart play 
an important role in protective effects of preconditioning against 
ischemia/reperfusion injury (29–31). The cardioprotection pro-
vided by mitoKATP channels could be affected by the administered 
anesthetic in the experimental animal studies.
The present study investigated whether the mitoKATP channels 
have any role on cardiovascular effects of TP or K anesthesia in 
rats. 5-HD, a specifi c mitoKATP channel blocker, increased MABP 
only in TP+5-HD group. But 5-HD did not cause any signifi cant 
change in MABP in K/X+5-HD group. On the other hand, blockage 
of mitoKATP channels by 5-HD decreased HR only in K/X+5-HD 
group. When the arrhythmia parameters were evaluated in TP+5-
HD and K/X+5-HD groups, there was an increase in arrhythmia 
parameters, especially in TP+5-HD group. There were studies 
about important role of the mitoKATP channels in antiarrhythmic 
effects of nicorandil, 3-pyridyl pinacidil or exercise against to 
I/R injury (32, 33). Furthermore, it has been demonstrated that 
increase in mitoKATP channel activity by diazoxide in isolated rat 
cardiomyocytes is inhibited by TP and R-ketamine but not by S-
ketamine or xylazine (34). The different interaction with mitoKATP 
channels and the anesthetic could refl ect hemodynamic parameters.
It has been known that the hemodynamic parameters are close-
ly related with arrhythmia parameters. Thus the severe arrythmo-
genic effect of TP could be associated with the increase in the 
MABP when mitoKATP channels are blocked. In addition to this, it 
has been reported that decrease in HR could play a cardioprotec-
tive role against ischemia/reperfusion injury (35). Similarly in the 
present study, 5-HD induced decrease in HR in K/X+5-HD group 
may cause cardioprotection in arrhythmia scores.
In conclusion, mitoKATP channels that play important role in 
cardioprotection have also effects on K and T anesthesia. The pres-
ent investigation has shown the fi rst time to the best of our knowl-
edge, mitoKATP channels blockage by 5-HD differently refl ected 
the hemodynamic parameters and arrhythmia scores dependent on 
the anesthesia type: K or TP. So, it is one of the important steps to 
select the right anesthetic for cardiovascular experimental studies, 
especially for those including mitoKATP channels because of the 
different interaction of K or TP with mitoKATP channels. 
Fig. 1. Changes in mean arterial blood pressure in TP control (n = 5), K/X 
control (n = 5), TP+5-HD (n = 6) and K/X+5-HD (n = 6) groups during the 
10-minute experimental protocol. *p < 0.05 compared with TP control.
Fig. 2. Changes in heart rate in TP control (n = 5), K/X control (n = 5), 
TP+5-HD (n = 6) and K/X+5-HD (n = 6) groups during the 10-min-
ute experimental protocol. * p < 0.05 vs compared with K/X control.
Fig. 3. Changes in arrhythmia incidence (%, ventricular ectopic beat, 
tachycardia and fi brilation) during the 10-minute experimental pro-
tocol in TP control (n = 5), K/X control (n = 5), TP+5-HD (n = 6) and 
K/X+5-HD (n = 6) groups. *; vs compared with own control, +; vs 
compared with K/X+5-HD group, p<0.05.
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